immune checkpoint inhibitor

The HIMALAYA trial demonstrates durable overall survival benefits and manageable safety of STRIDE (tremelimumab plus durvalumab) versus sorafenib in unresectable hepatocellular carcinoma after five years of follow-up.

Enhancing Fibrosis Scoring in MASH: The Role of AI-Enhanced Digital Pathology
HEC88473 Dual GLP-1/FGF21 Agonist: Advancing Treatment for MASLD and T2DM with Promising Safety and Efficacy
AZD2693: Targeting PNPLA3 148M Variant as a Precision Therapy for Metabolic Steatohepatitis
Rapirosiran: A Promising RNAi Therapy Targeting HSD17B13 in Metabolic Dysfunction-Associated Steatohepatitis
The THEMATIC Trial: Advancing Microbiota Transplantation to Prevent Hepatic Encephalopathy Recurrence in Cirrhosis

About us
Contact us
MedXY story
Privacy Policy
Subscribe Now!
账号

English
日本語
Tiếng Việt
中文

aging AI artificial intelligence blood pressure breast cancer béo phì cardiovascular health cardiovascular risk clinical trial COPD COVID-19 diabetes diet dinh dưỡng exercise GLP-1 health heart failure HFpEF Hypertension immunotherapy inflammation longevity MASH MASLD mental health metformin Mortality nutrition obesity Pregnancy prevention public health randomized trial semaglutide sexual health Suy Tim sức khỏe tim mạch thử nghiệm lâm sàng tirzepatide type 2 diabetes weight loss wellness women's health 心力衰竭

Your health, we care

Scroll to Top